Price History

Hover for the daily close. The dotted line marks the period open.

Compare NMRA with… →

NMRA Key Statistics

As of Sep 4, 2026

Trading

Open: $1.35
Previous Close: $1.35
Day's Range: 1.29–1.36
52-Week Range: 0.83–3.65
Volume: 547.00K
Beta: 2.74

Valuation

Market Cap: $246.14M
P/E Ratio: unprofitable
EPS (ttm): −1.20

Financials (FY)

Revenue (FY): $0.00
Net Income (FY): −$236.93M
Profit margin: 0.00%
Shares Outstanding: 187.90M
1-Year Return: −19.63%

Dividend and dates

Earnings Date: November 5, 2026estimated
Avg Volume: 1.90M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

NMRA Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

+0.29%−37.83%−83.11%−26.82%

2023*202420252026*

Year	Return
2026 (partial year)	−26.82%
2025	−83.11%
2024	−37.83%
2023 (partial year)	+0.29%

As of September 4, 2026.

NMRA Revenue and Earnings by Fiscal Year

FY ends December

RevenueNet income

2022202320242025

Fiscal year	Revenue	Net income	Net margin
2025	$0.00	−$236.93M	—
2024	$0.00	−$243.79M	—
2023	$0.00	−$235.93M	—
2022	$0.00	−$130.90M	—

Fiscal year	Revenue	Gross profit	Operating income	Net income	Net margin
2025	$0.00	—	−$241.16M	−$236.93M	—
2024	$0.00	—	−$263.46M	−$243.79M	—
2023	$0.00	—	−$252.10M	−$235.93M	—
2022	$0.00	—	−$135.87M	−$130.90M	—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

NMRA Valuation vs Biotechnology Median

Median of 656 stocks

Metric	NMRA	Biotechnology median	vs median
Profit margin	0.00%	0.00%	0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Neumora Therapeutics, Inc. (NMRA) carries a market capitalisation of $246.14M. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 63 employees.

The most recent close on file for NMRA is $1.31, dated September 4, 2026. That is −$0.04 (−2.96%) against the previous close. Over the past 52 weeks the price has ranged from $0.83 to $3.65. The latest close sits 57.83% above that 52-week low.

Financial Health

In fiscal 2025, Neumora Therapeutics, Inc. reported revenue of $0.00. The same year closed with a net loss of $236.93M. Profit margin runs at 0%. Trailing earnings per share are −1.2.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

Over the trailing twelve months the price has returned −19.63%. Across 3 years the annualized return works out at −57.45%. Beta against the wider market is reported at 2.74. Daily returns over the trailing 3 years annualize to a volatility of 111.34%.

Growth & Income

The record shows no dividend for NMRA.

Across the complete calendar years on file, 2024 returned −37.83% and 2025 returned −83.11%. 2026 is still running; the price is −26.82% year to date.

Peer Comparison

Neumora Therapeutics, Inc. (NMRA) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company	Ticker	Market Cap	P/E Ratio
Neumora Therapeutics, Inc.	NMRA	$246.14M	—
Vertex Pharmaceuticals Incorporated	VRTX	$138.42B	32.5
Regeneron Pharmaceuticals, Inc.	REGN	$85.22B	20.5
argenx SE	ARGX	$64.25B	40.1

The Biotechnology industry average P/E ratio is 12.6x. Neumora Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

ARGX

argenx SE

$64.25B

MRNA

Moderna, Inc.

$58.11B

RVMD

Revolution Medicines, Inc.

$45.01B

ONC

BeOne Medicines AG

$40.53B

View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

JNJ

Johnson & Johnson

$663.28B

ABBV

AbbVie Inc.

$453.19B

MRK

Merck & Co., Inc.

$370.89B

UNH

UnitedHealth Group Incorporated

$356.47B

View all Healthcare stocks →

About Neumora Therapeutics, Inc.

Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in the United States. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in Phase 1b clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-861 and NMRA-898, a M4 muscarinic receptor positive allosteric modulators (PAMs) for schizophrenia and other neuropsychiatric disorders. In addition, the company's preclinical phase product includes NMRA-GCase, an activator program for the treatment of Parkinson's Disease; NMRA-CK1d, a casein kinase 1 isoform delta (CK1d) inhibitor program for Amyotrophic Lateral Sclerosis; and NMRA-215 a brain-penetrant oral NLRP3 inhibitor for the treatment of obesity. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.

Visit website →

Neumora Therapeutics, Inc. (NMRA) Stock Analysis